Eli Lilly to Invest $3 Billion in New European Manufacturing Facility at Leiden Bio Science Park, Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain Eli Lilly and Company ...

November 04, 2025 | Tuesday | News
INOVIO Completes BLA Submission for INO-3107, a DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...

November 04, 2025 | Tuesday | News
Virax Biolabs Completes Full UK Recruitment for ViraxImmune™ Clinical Study on Long COVID and Related Syndromes

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses t...

November 04, 2025 | Tuesday | News
Thermo Fisher Scientific to Acquire Clario for $8.9 Billion to Accelerate Digital Transformation of Clinical Research

Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margi...

October 30, 2025 | Thursday | News
IN8bio Adds The Ohio State University as New Clinical Site for INB-100 Phase 1 Trial

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...

October 30, 2025 | Thursday | News
Avance Clinical Launches CNS Center of Excellence to Advance Global Biotech Trials

Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced th...

October 29, 2025 | Wednesday | News
Jupiter Neurosciences Secures Up to $20 Million in Flexible Financing from Yorkville Advisors to Advance Parkinson’s Trial and Nugevia™ Expansion

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...

October 28, 2025 | Tuesday | News
Zai Lab Reports 68% Response Rate for DLL3-Targeted ADC Zocilurtatug Pelitecan in Second-Line Small Cell Lung Cancer

- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...

October 27, 2025 | Monday | Reports
Xencor Reports Promising Phase 1 Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose ...

October 27, 2025 | Monday | News
Gelteq Initiates Preclinical Trial with Monash University to Advance Oral Delivery of Oily and Poorly Soluble Drugs

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 24, 2025 | Friday | News
Ipsen to Acquire ImCheck Therapeutics to Advance Promising AML Immunotherapy ICT01

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...

October 23, 2025 | Thursday | News
Sharp Commits $100 Million to Expand Sterile and Packaging Capacity Across U.S. and Europe

    Sterile fill/finish capacity added in Lee, MA, and injectable assembly and packaging capacity added in the Netherlands, Belgium, Allent...

October 23, 2025 | Thursday | News
Salvat Secures FDA Approval for Clotic®, the First Targeted Therapy for Otomycosis with Orphan Drug Designation

SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation     Th...

October 22, 2025 | Wednesday | News
BriaCell Partners with Memorial Sloan Kettering to Accelerate Development of Next-Generation Personalized Immunotherapy

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...

October 22, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close